Navigation Links
Senetek PLC Reports Second Quarter 2008 Financial Results
Date:8/14/2008

Cash on Hand Totals $17.8 million at June 30

Investor Conference Call Scheduled for September 5

NAPA, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced financial results for the quarter ended June 30, 2008.

Revenue for the quarter ended June 30, 2008 was $691,000, compared with $471,000 reported in the second quarter of 2007.

Net income for the quarter ended June 30, 2008 totaled $257,000, or $0.03 per share compared to a net loss of $397,000 a loss of $0.05 per share in the second quarter of 2007. Net income for the quarter ended June 30, 2008 included other income of $1,125,000 from the previously announced settlement with Triax Aesthetics LLC and a service provider.

Cash and cash equivalents totaling $17,803,000, or $2.33 per share at June 30, 2008 represent the resources necessary to meet operating requirements for the foreseeable future.

Senetek's Board of Directors will meet on August 28, 2008. Matters to be addressed include a capital restructure to facilitate both a possible share buyback and dividend program and a Nominating Committee review of Board candidates.

Senetek will conduct a teleconference call for investors on Friday, September 5, 2008 at 9:00 a.m. Pacific, 12:00 p.m. Eastern to provide an update to include:

* Pyratine-6(TM) -- current success in U.S. physician market and Q4 2008

launch plan.

* Invicorp(R) EU -- effect of Ardana Bioscience Ltd. insolvency.

* Invicorp(R) US -- Plethora Solutions Ltd. report on status of regulatory

pathway.

* Reliaject(R) -- update on Ranbaxy's progress.

* Corporate and Product Public Relations.

The domestic dial-in number is 877-593-8638; the international dial-in number is 706-634-9240, conference ID 60464120. Mr. Frank J. Massino, Chairman and CEO, Mr. Phillip Rose, Chief Operating Officer and Mr. William F. O'Kelly, Chief Financial Officer, will participate to the call. Replay of the conference call will be available until September 12, 2008. Domestic Replay dial-in 800-642-1687, International Replay dial-in 706-645-9291, replay conference ID 60464120.

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek PLC Reports First Quarter 2008 Financial Results
2. Senetek PLC Announces Appointments of Key Personnel
3. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
4. Cadus Reports Second Quarter 2008 Results
5. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
6. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
7. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
8. Derma Sciences Reports Second Quarter 2008 Results
9. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. NeurogesX Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)...  The Allen Institute for Cell Science has ... available collection of gene edited, fluorescently tagged human ... structures with unprecedented clarity. Distributed through the Coriell ... a crucial first step toward visualizing the dynamic ... human cells healthy and what goes wrong in ...
(Date:11/30/2016)... , Nov. 30, 2016  Tempus, a technology ... care, and Penn,s Abramson Cancer Center have partnered ... positive response to immunotherapy treatment based on next ... As part of a research collaboration, Tempus will ... melanoma cancer patient data to Penn. Utilizing next-generation ...
(Date:11/30/2016)... , 30. November 2016   ... hat heute die Unterzeichnung einer Reihe von ... zufolge wird Evotec AG Screeningleistungen für Mercks ... bereitstellen. Der Zugriff auf diese Bibliotheken in ... eröffnet einen schnelleren Weg zur Ermittlung und ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):